SVS VQI data being “fortified” to shed light on long-term paclitaxel device use in the periphery

Kim Hodgson (Springfield, USA), president of the Society for Vascular Surgery (SVS) for 2019–20 spoke to Vascular News at the organisation’s Vascular Annual Meeting in June to share the most influential data to have emerged from the Vascular Quality Initiative. He says the  SVS’ Paclitaxel Task Force is working with “granular and robust” long-term data from the VQI to further fortify it, in order to shed light on the ongoing controversy regarding the potential raised mortality risk associated with the use of paclitaxel devices in the periphery.